You are here: Home:Audio Program Guide: BCU 7 | 2005

  Go to interview with Rowan T Chlebowski, MD, PhD
Go to interview with Eric P Winer, MD
Go to interview with Harry D Bear, MD, PhD
Go to interview with Juliann M Smith, MD

To listen to individual tracks now, click the icon. To download tracks to a CD, right-click the icon for your preferred file type. Files are provided in WMA for users with Windows Media Player or MP3 for users with other audio players.

Rowan T Chlebowski, MD, PhD
Dr Chlebowski is a Professor of Medicine at UCLA
School of Medicine and Chief of Medical Oncology at
Harbor-UCLA Medical Center in Torrance, California.

Click here to download the entire interview
Track 1 Introduction by Neil Love, MD
Track 2 Women’s Intervention Nutrition Study: Dietary fat reduction in postmenopausal women with primary breast cancer
Track 3 Impact of dietary fat reduction on recurrence according to ER phenotype
Track 4 Results from Women’s Health Initiative trials of postmenopausal hormone therapy
Track 5 Tolerability of aromatase inhibitors versus tamoxifen
Track 6 Increased incidence of cardiac toxicity and stroke associated with letrozole in BIG 1-98

Track 7 Mathematical modeling to determine optimal adjuvant hormonal therapy
Track 8 Role of bisphosphonates to offset aromatase inhibitor-induced bone loss
Track 9 Selection of up-front hormonal therapy
Track 10 Clinical use of ovarian ablation with an aromatase inhibitor
Track 11 Time course for switching from tamoxifen to an aromatase inhibitor
Track 12 Management of postmenopausal women after five years of adjuvant tamoxifen
Track 13 Rationale for up-front use of aromatase inhibitors
Track 14 Postmenopausal hormone therapy for breast cancer survivors
Track 15 Potential role of tibolone to alleviate menopausal symptoms in patients with breast cancer
Track 16 Impact of race and ethnicity on breast cancer histology subtype
Eric P Winer, MD
Dr Winer is the Director of the Breast Oncology
Center at the Dana-Farber Cancer Institute and
Associate Professor of Medicine at Harvard Medical
School in Boston, Massachusetts.

Click here to download the entire interview
Track 1 Introduction by Dr Love
Track 2 ECOG-E2100: Paclitaxel with or without bevacizumab as first-line therapy for metastatic breast cancer
Track 3 Clinical use of bevacizumab in combination with chemotherapy
Track 4 Potential benefits of nanoparticle albumin-bound (nab) paclitaxel
Track 5 Eligibility criteria for ECOG-E2100
Track 6 Bevacizumab in the second- and third-line settings
Track 7 Proposed ECOG pilot trial examining the role of adjuvant bevacizumab
Track 8 Combined analysis of NSABP-B-31/NCCTG-N9831 trials of adjuvant trastuzumab
Track 9 Cardiac toxicity induced by adjuvant trastuzumab
Track 10 Concurrent versus sequential administration of adjuvant trastuzumab and chemotherapy
Track 11 Adjuvant trastuzumab for patients with node-negative disease
Track 12 Combining hormonal therapy with trastuzumab and chemotherapy in the adjuvant setting
Track 13 Time course for initiating therapy with adjuvant trastuzumab
Track 14 Need to facilitate completion of clinical trials more rapidly
Track 15 Future directions in adjuvant trials for patients with HER2- positive disease
Track 16 Management of patients who relapse on adjuvant trastuzumab
Track 17 Quality control with HER2 testing in community practice

Harry D Bear, MD, PhD
Dr Bear is Chairman of the Division of Surgical Oncology,
Professor of Surgery and Microbiology and Immunology
and Walter Lawrence Jr Distinguished Professor in
Oncology at Virginia Commonwealth University School of
Medicine’s Massey Cancer Center in Richmond, Virginia. 

Click here to download the entire interview

Track 1 Introduction by Dr Love
Track 2 NSABP-B-27: Neoadjuvant AC versus neoadjuvant AC followed by docetaxel versus neoadjuvant AC followed by adjuvant docetaxel
Track 3 AC followed by docetaxel as adjuvant therapy
Track 4 NSABP-B-30: AC followed by docetaxel versus TAC versus AT as adjuvant therapy for patients with nodepositive disease

Track 5 Potential design of future NSABP neoadjuvant/adjuvant trial
Track 6 Management of patients with residual tumor burden following surgery
Track 7 NSABP-B-35: Anastrozole versus tamoxifen for DCIS
Track 8 NSABP-B-32 trial of sentinel lymph node biopsy
Track 9 Development and validation of the Oncotype DX™ assay
Track 10 NSABP-B-39: Conventional whole breast irradiation versus partial breast irradiation
Track 11 Potential benefits of core needle biopsy versus excisional biopsy
Track 12 Selection of surgical treatment following neoadjuvant chemotherapy
Track 13 Use of ferromagnetic particles in conjunction with MRI to identify positive lymph nodes

Juliann M Smith, MD
Eisenhower Lucy Curci Cancer Center

Click here to download the entire interview

Track 1 Introduction by Dr Love
Track 2 Case discussion: A 44-year-old premenopausal medical oncologist with node-positive,
ER-positive, HER2-positive breast cancer
Track 3 Impact of breast cancer diagnosis and treatment on clinical decision-making
Track 4 Patient preference for aggressive treatments

Track 5 Medical oncologists’ underestimation of the side effects of chemotherapy

Track 6 Importance of interactions between medical oncologists and cancer patients